

DOCKET NO.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jerome B. Zeldis, et al.

Confirmation No.: 8455

Application No.: 10/820,397

Group Art Unit: 1614

Filing Date: April 8, 2004

Examiner: Raymond J. Henley III

For: **Methods For Treatment Of Cognitive And Menopausal Disorders With D-Threo Methylphenidate**

DATE OF DEPOSIT: October 20, 2006

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Heather Kite

TYPED NAME: Heather Kite

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.


- ☒ Copies of reference numbers 209-222 listed on the attached Form PTO-1449 are enclosed herewith.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:

October 20, 2006



Walter C. Frank
Registration No. 52,911

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1614
	Confirmation No. 8455	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/D.S./	209	Aoyama et al., Kinetic Analysis of Enantiomers of threo-Methylphenidate and Its Metabolite in Two Healthy Subjects after Oral Administration as Determined by a Gas Chromatographic-Mass Spectrometric Method, 1990 , Vol. 79, No. 6, pp. 465-469
	210	Arnold, L. E. et al., "A Double-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children with Attention Deficit Hyperactivity Disorder," 2004 , <i>J. Am. Child Adolesc. Psychopharmacol.</i> 14(4):542-554
	211	Ding, Y-S. et al., "Brain Kinetics of Methylphenidate (Ritalin) Enantiomers After Oral Administration," <i>Synapse</i> , September 2004 , 53, 168-175
	212	Jaffe, P., "Will the real Ritalin please stand up?," <i>A Quarterly Newsletter by ad for Adults who have Attention Deficit Disorder</i> , 1992 , Issue #10, 3 pages
	213	Jarvi et al., "Bioequivalence of Methylphenidate Tablets," Abstract PPDM 8169, <i>Pharmaceutical Research</i> Vol. 7, No. 9, 1990 , 2 pages
	214	Meyer, et al., "Bioequivalence of Methylphenidate Immediate-Release Tablets Using a Replicated Study Design to Characterize Intrasubject Variability," <i>Pharmaceutical Research</i> , Vol. 17, No. 4, 2000 , 381-384
	215	Patrick et al., "Distribution of Methylphenidate and P-Hydroxymethylphenidate in Rats," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1984 , Vol. 231, No. 1, 61-65
	216	Patrick, K. S. et al., "New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder," <i>Expert Opin. Drug Deliv.</i> , 2005 , 2(1), 121-143
/D.S./	217	Patrick, K.S. et al., Poster Abstract 267, "Synthesis, Pharmacology and Human Metabolic Formation of Ethylphenidate: the Transesterification Product of Methylphenidate and Ethanol," <i>The 56th Southeast Regional Meeting 2004</i> , November 10-13, 2004 , 2 pages

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	218	Quinn, D. et al., "Comparative pharmacodynamics and plasma concentrations of <i>d-threo</i> -methylphenidate hydrochloride after single doses of <i>d-threo</i> -methylphenidate hydrochloride and <i>d,l-threo</i> -methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder," November 2004, <i>J. Am. Child Adolesc. Psychiatry</i> 43(11):1422-1429	
	219	Silva, R. et al., "Open-Label Study of Dexmethylphenidate Hydrochloride in Children and Adolescents with Attention Deficit Hyperactivity Disorder," 2004, <i>J. Child Adolesc. Psychopharmacol.</i> 14(4):555-563	
	220	Volkow, N.D. et al., "Evidence That Methylphenidate Enhances the Saliency of a Mathematical Task by Increasing Dopamine in the Human Brain," Am. J. Psychiatry, July 2004, 161(7), 1173-1180	
	221	Weiss, M., et al., "A post hoc analysis of <i>d-threo</i> -methylphenidate hydrochloride (Focalin) versus <i>d,l-threo</i> -methylphenidate hydrochloride (Ritalin)," <i>J. Am. Acad. Adolesc. Psychiatry</i>, November 2004, 43(11), 1415-1421	
/D.S./	222	Wigal, S., et al., "A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and <i>d,l-threo</i> -methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder," <i>J. Am. Acad. Adolesc. Psychiatry</i>, November 2004, 43(11), 1406-1414	

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008